论文部分内容阅读
目的:观察益气舒心丸对急性冠脉综合征(ACS)患者内皮功能、相关炎症因子和P-选择素的影响,探讨CAG术中冠脉血流储备的影响机制。方法:将92例ACS患者随机分为两组。对照组45例予西医常规治疗,治疗组47例在西医治疗基础上予益气舒心丸,治疗6个月。复查冠状动脉造影,测定治疗前后一氧化氮(NO)/内皮素-1(ET-1)、高敏C-反应蛋白(hs-CRP)、可溶性血管细胞黏附分子1(s VCAM-1)、P-选择素(P-selectin)以及冠脉血流储备(CFR)各指标的变化。结果:治疗后,治疗组的ET-1、hs-CRP、s VCAM-1、P-selectin较治疗前降低,NO较治疗前升高;治疗后两组比较,治疗组ET-1、hs-CRP、s VCAM-1、P-selectin低于对照组,NO高于对照组,差异均有统计学意义(P<0.05)。治疗后,治疗组的CFR高于对照组,差异有统计学意义(P<0.05)。结论:益气舒心丸可改善ACS患者血管内皮功能,抑制炎症反应,抑制血小板活化,增加冠脉动脉血流储备。
Objective: To observe the effect of Yiqi Shuxin Pill on endothelial function, related inflammatory factors and P-selectin in patients with acute coronary syndrome (ACS), and to explore the mechanism of coronary flow reserve in CAG. Methods: 92 patients with ACS were randomly divided into two groups. In the control group, 45 cases were routinely treated with western medicine. In the treatment group, 47 cases were treated with Yiqi Shuxin Pill for 6 months on the basis of western medicine treatment. Coronary angiography was performed and the levels of NO / ET-1, hs-CRP, s VCAM-1, P - P-selectin (P-selectin) and changes in coronary flow reserve (CFR) indicators. Results: After treatment, the levels of ET-1, hs-CRP, VCAM-1 and P-selectin in the treatment group were lower than those before treatment, CRP, s VCAM-1, P-selectin were lower than the control group, NO was higher than the control group, the difference was statistically significant (P <0.05). After treatment, the treatment group CFR higher than the control group, the difference was statistically significant (P <0.05). Conclusion: Yiqi Shuxin Pills can improve endothelial function, inhibit inflammatory reaction, inhibit platelet activation and increase coronary blood flow reserve in ACS patients.